LISTING OF THE CLAIMS:

The current claim set should now replace any claim set of record.

1. (**Currently amended**) A complex comprising a compound of one of formula I - VIII, XII or XIII, in association with an adrenomedullin (AM) peptide, wherein formulas I - VIII, XII and XIII are:



Formula I

wherein:

K is OR_{32}, SR_{32}, or $NR_{33}R_{34}$ where R_{32} is H or lower alkyl, and R_{33} and R_{34} are the same or different and each is selected from H and lower alkyl;

Ar is aryl optionally substituted aryl optionally substituted with one or more groups selected from -OH, $-NH_2$, -SH, halogen and hydrocarbyl;

n is an integer from 1-3; and

R_1, R_2 and R_3 are the same or different and is each selected from H, hydrocarbyl and a heterocyclic ring; or

R_1 and R_2 together form a heterocyclic ring including the intervening nitrogen, and R_3 is selected from H, hydrocarbyl and a heterocyclic ring; or

R_1 is selected from H ~~or~~ and hydrocarbyl and R_2 and R_3 together form a heterocyclic ring including the intervening nitrogen;

Formula II

wherein:

R_4 and R_5 may be the same or different and each is an aryl group substituted with -C(O)K, and optionally further substituted with one or more groups selected from -OH, $-NH_2$, -SH, halogen, hydrocarbyl and a heterocyclic ring, where K is as defined above; and

m is an integer from 1-3;



Formula III

wherein:

K is as defined above;

Y is selected from CH_2, O, S and NH; and

R_6 is aryl optionally substituted with one or more groups selected from -OH, -NH_2, -SH, halogen, hydrocarbyl and a heterocyclic ring;



Formula IV

wherein:

R_7 is aryl optionally substituted with one or more groups selected from -OH, -NH_2, -SH, halogen, a heterocyclic ring and hydrocarbyl; and

R_8 and R_9 are the same or different and are each hydrocarbyl, optionally substituted with one or more halogens or lower alkyl groups, or

R_8 and R_9 together form a heterocyclic ring having five, six or seven atoms, including the intervening nitrogen and optionally containing other heteroatoms, and also optionally substituted with one or more halogens or lower alkyl groups;



Formula V

wherein:

K is as defined above; and

R_{10} and R_{11} are the same or different and each is an aryl group, optionally substituted with a second aryl group that may be the same or different and the aryl groups may be substituted with one or more groups selected from -OH, -NH_2, -SH, halogen, a heterocyclic ring and hydrocarbyl;



Formula VI

wherein:

p is an integer from 1-3;

M_1, M_2, and M_3 are the same or different and each is S or O;

Z is S, [[C]] or P;

R is hydrocarbyl or OR_{35}, where R_{35} is H or hydrocarbyl; and

R_{12} and R_{13} are the same or different and each is hydrocarbyl, a heterocyclic ring or lower alkyl, or R_{12} and R_{13} together form a ring;



Formula VII

wherein:

K is as defined above;

r is and integer from 1-3;

R_{14} and R_{15} are the same or different and each is aryl optionally substituted with one or more groups selected from -OH, $-NH_2$, -SH, halogen, a heterocyclic ring and hydrocarbyl; and

R_{16} and R_{17} are the same or different and each is hydrocarbyl or a hetercyclic ring;



Formula VIII

wherein:

s is an integer from 1-10;

R_{20}, R_{21}, R_{22} and R_{23} are the same or different and each is H, aryl, optionally substituted with one or more halogen or lower alkyl groups, hydrocarbyl and a heterocyclic ring; and

R_{18}, R_{19} are the same or different and each is aryl optionally substituted with one or more groups selected from -OH, $-NH_2$, -SH, halogen and lower alkyl;



Formula XII

wherein:

t is an integer from 1-5;

u is an integer from 1-2; and

R_{24} is selected from H, a heteroyclic ring and hydrocarbyl, optionally substituted by halogen; and



Formula XIII

wherein:

Q is selected from CH_2, NH, S and O; and

Z_1 and Z_3 are the same or different and selected from CH_3, NH_2, OH and SH.

or tautomers thereof,

or a pharmaceutically acceptable salt thereof.

2 - 4. **(Canceled)**

5. **(Currently amended)** A complex comprising a compound of one of



Formula XIV

wherein:

v is an integer from 1-3; and

G_1 and G_2 are the same or different and each is selected from CH_2, NH, S and O;

Formula XVI



or the corresponding quinone



wherein:

R_{25}, R_{26}, R_{27}, and R_{28} are the same or different and each is selected from halogen and hydrocarbyl, particularly lower alkyl; and



Formula XVII

wherein:

K is as defined above, and

R_{29} and R_{30} are the same or different and each is aryl optionally substituted with one or more groups selected from -OH, $-NH_2$, -SH, halogen and hydrocarbyl,

or a pharmaceutically acceptable salt thereof;

in association with a gastric releasing peptide (GRP).

6 - 8. **(Canceled)**

9. (**Currently amended**) A pharmaceutical composition comprising a compound of one of formula I - VIII, XII, or XIII as defined in claim 1, ~~or one of formula XIV, XVI or XVII as defined in claim 5,~~ or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

10. (**Currently amended**) The pharmaceutical composition of claim 9, wherein the compound is of one of formula I′ - XIII′ ~~as defined in claim 2, or one of formula XIV′, XVI′, or XVII′ as defined in claim 6~~ or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier:



formula I′



formula II′



formula III′



formula IV′,



formula V′,



formula VI′,



formula VII′,



formula VIII′,



formula IX′,



formula X′,



formula XI′,



formula XII′, and



formula XIII′.

11. (**Currently amended**) A method for inhibiting an activity of an AM peptide, comprising contacting the peptide with an effective amount of a pharmaceutical composition comprising the compound of one of formula I - VII as defined in claim [[1]] 9.

12 - 16. (**Canceled**)

17. (**Currently amended**) A method for treating a condition that is mediated by over-expression and/or activity of AM, comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising the compound of one of formula I – VII, as defined in claim [[1]] 9.

18 - 19. (**Canceled**)

20. (**Currently amended**) A method for stimulating an activity of an AM peptide, comprising contacting the peptide with an effective amount of a pharmaceutical composition comprising the compound of one of formula VIII, XII or XIII, as defined in claim [[1]] 9.

21 - 25. (**Canceled**)

26. (**Currently amended**) A method for treating a condition that is mediated by under-expression and/or activity of AM, comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising the compound of one of formula VIII, XII or XIII, as defined in claim [[1]] 9.

27 - 28. **(Canceled)**

29. (**Currently amended**) A method for inhibiting an activity of a GRP peptide, comprising contacting the peptide with an effective amount of a pharmaceutical composition comprising compound of formula XIV or XVI, as defined in claim ~~5~~ 76.

30 - 34. (**Canceled**)

35. (**Currently amended**) A method for treating a condition that is mediated by over-expression and/or activity of GRP, comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising the compound of formula XIV or XVI, as defined in claim ~~5~~ 76.

36 - 37. (**Canceled**)

38. (**Currently amended**) A method for stimulating an activity of a GRP peptide, comprising contacting the peptide with an effective amount of a pharmaceutical composition comprising the compound of formula XVII, as defined in claim ~~5~~ 76.

39 - 43. (**Canceled**)

44. (**Currently amended**) A method for treating a condition that is mediated by under-expression and/or activity of GRP, and/or that would benefit from increased expression of GRP comprising administering to a patient in need of such treatment an effective amount of a pharmaceutical composition comprising the compound of formula XVII, as defined in claim ~~5~~ 76.

45 - 46. (**Canceled**)

47. (**Currently amended**) A method for detecting an AM peptide, comprising

contacting a sample suspected of containing the peptide with a pharmaceutical composition comprising one or more detectably labeled compounds of formula I through VIII, or formula XII through XIII, as defined in claim [[1]] 9, and

detecting labeled compound that is associated with the peptide.

48. (**Canceled**)

49. (**Currently amended**) A method for detecting a GRP peptide, comprising

contacting a sample suspected of comprising the peptide with a pharmaceutical composition comprising one or more detectably labeled compounds of formula XIV, XVI or XVII, as defined in claim ~~5~~ 76 or



Formula XV wherein

R_1 is: $-R_5-(CH_2)_n-CH(R_6)OH$, and R_5 is NH, S or O, R_6 is H or CH_3; and n is an integer from 1-4;

R_2 is NH_2, substituted amino or acetamide;

R_3 is H, halogen, CH_3, or CF_3; and

R_4 is H, alkyl, substituted alkyl, alkenyl, alkoxy or halogen; and

detecting labeled compound that is associated with the peptide.

50 - 52. (**Canceled**)

53. (**Currently amended**) A kit suitable for treating a subject suffering from a condition mediated by aberrant expression and/or activity of adrenomedullin (AM), comprising a pharmaceutical composition comprising one or more compounds of formula I - VIII, XII or XIII, as defined in claim ~~1~~ 9, ~~or a pharmaceutical composition comprising said compound(s) and a pharmaceutically acceptable carrier,~~ and, optionally, a container or packaging material.

54. (**Canceled**)

55. (**Currently amended**) A kit suitable for treating a subject suffering from a condition mediated by an aberrant expression and/or activity of gastrin releasing peptide (GRP), comprising a pharmaceutical composition comprising one or more of the compounds of formula XIV, XVI or XVII, as defined in claim ~~5~~ 76, ~~or a pharmaceutical composition comprising said compound(s) and a pharmaceutically acceptable carrier,~~ and, optionally, a container or packaging material.

56. (**Canceled**)

57. (**Currently amended**) A kit suitable for detecting an AM peptide, comprising

a) a pharmaceutical composition comprising one or more compounds selected from formula I - VIII, XII ~~or~~ and XIII, as defined in claim [[1]] 9, ~~which~~ wherein the compound is detectably labeled, and, optionally,

b) means to detect the labeled compound associated with (bound to) the peptide.

58. (**Canceled**)

59. (**Currently amended**) A kit suitable for detecting a GRP peptide, comprising

a) a pharmaceutical composition comprising one or more compounds selected from formula XIV, XVI, XVII, ~~as defined in claim 5~~ and XV, as defined in claim 49, ~~which~~ wherein the compound is detectably labeled, and, optionally,

b) means to detect the labeled compound associated with (bound to) the peptide.

60 - 61. (**Canceled**)

62. (**Previously presented**) A method for inhibiting GRP-mediated angiogenesis in a subject in need of such treatment, comprising administering to the subject an effective amount of an agent that inhibits GRP,

provided that the GRP-mediated angiogenesis is not angiogenesis involved in tumor growth or metastasis.

63. (**Previously presented**) A method for preventing or treating condition mediated by GRP-mediated angiogenesis in a subject in need of such treatment, comprising administering to the subject an effective amount of an agent that inhibits GRP,

provided that the condition is not angiogenesis dependent tumor growth.

64 - 73. (**Canceled**)

74. (**Currently amended**) A method for treating low blood pressure or an eating disorder in a subject in need of such treatment, comprising administering to the subject an effective amount of a pharmaceutical composition comprising the compound of formula XV as defined in claim 49.

75. (**Canceled**)

76. (**New**) A pharmaceutical composition comprising a compound of one of formula XIV, XVI or XVII as defined in claim 5, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

77. (**New**) A pharmaceutical composition of claim 76, wherein the compound is one of formula XIV', XVI' or XVII', or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier:
Formula XIV',



Formula XVI',



or the corresponding quinone



or Formula XVII'



.